Novo Nordisk Foundation
The Novo Nordisk Foundation, headquartered in Denmark (DK), is a prominent philanthropic organisation dedicated to improving global health and advancing scientific research. Established in 1923, the foundation has played a pivotal role in supporting diabetes care, obesity treatment, and other chronic diseases, reflecting its commitment to enhancing the quality of life for patients worldwide. With a focus on funding innovative research and development, the Novo Nordisk Foundation has significantly contributed to the biopharmaceutical industry, particularly in the fields of diabetes and hormone replacement therapies. Its unique approach combines financial support with strategic partnerships, fostering groundbreaking advancements in medical science. Recognised for its substantial contributions, the foundation continues to maintain a leading position in the healthcare sector, driving impactful change through its various initiatives and collaborations.
DitchCarbon Score
How does Novo Nordisk Foundation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novo Nordisk Foundation's score of 37 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Novo Nordisk Foundation's reported carbon emissions
In 2023, Novo Nordisk Foundation reported total carbon emissions of approximately 2,174,300,000 kg CO2e, comprising 78,000,000 kg CO2e from Scope 1, 15,000,000 kg CO2e from Scope 2, and a significant 2,143,300,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions included major contributions from purchased goods and services (approximately 1,018,000,000 kg CO2e) and upstream transportation and distribution (about 108,000,000 kg CO2e). In 2024, emissions increased slightly, with total emissions reaching approximately 2,160,000,000 kg CO2e, including 85,000,000 kg CO2e from Scope 1, 174,000,000 kg CO2e from Scope 2, and 2,160,000,000 kg CO2e from Scope 3. The largest components of Scope 3 emissions were again from purchased goods and services (approximately 1,215,000,000 kg CO2e) and business travel (about 188,000,000 kg CO2e). Despite these figures, there are currently no publicly disclosed reduction targets or initiatives from the Novo Nordisk Foundation aimed at decreasing their carbon footprint. The Foundation's commitment to addressing climate change remains a critical focus, but specific strategies or targets have not been outlined.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 76,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,000,000 | 00,000,000 | 000,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novo Nordisk Foundation is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
